Medical Affairs value isn't what you think it is

Medical Strategy, Medical Leadership, Medical Affairs

Medical Affairs functions have spent years building the case for their value. Frameworks, metrics, dashboards, impact stories, insight delivery. The work is real, the effort is genuine, and most of it misses the point entirely.

Apr 1^st • 5 mins read

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

headcount, reduction, revenue per employee

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.  Among the 17 largest pharma companies analyzed in a Fierce Pharma review of annual reports, only five logged a head count increase in 2025…

Mar 23^rd • 10 mins read

MSL Hiring and Recruitment: 5 Ways to Support Diversity and Inclusion

Medical Science Liaison hiring, diversity and inclusion recruitment, diverse interview panel, employee referral program, diversity sourcing strategies

While the COVID-19 pandemic wreaked havoc on many industries, Medical Science Liaison hiring was steady throughout 2020 and continues to remain strong in 2021. The one change in hiring that has become evident is the increase in recruitment practices that support diversity and inclusion. While we may…

May 19^th • 2 mins read

Biased by design? Clinical trials and patient benefit in oncology

clinical trial design, drug development, drug registration, patient benefit, risks of bias

The study by Naci et al. raises numerous questions relating to the design characteristics, risks of bias and reporting of pivotal clinical trials in oncology. These findings add to the existing body of evidence that suggests drug development in oncology is not delivering the clinical benef…

Nov 27^th • 3 mins read

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development

clinical pharmacology, FDA reviews, PMR, PMC, molecular entitites, anticancer drug development

The article discusses optimizing oncology drug development, focusing on the impact of pharmacokinetic factors like food effects and drug interactions. It recommends early evaluation of these factors to enhance dosing accuracy and patient compliance. Advanced modeling and simulation are suggested to …

Mar 11^th • 15 mins read